ResearcherSecond Hospital of Shandong UniversityActive in the last 2 years

Jinlong Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5234-9285; OpenAlex author ID A5031318828. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2025: 2 papers

Papers 2

LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. Co-author DOI 10.1186/s12951-025-03550-4 ↗
High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapies. Co-author DOI 10.21037/tcr-24-1832 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaoshi Zhang · 1 shared paper, 2025 · strength 0.37
- Paper High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapie… DOI 10.21037/tcr-24-1832 ↗
Chao Yu · 1 shared paper, 2025 · strength 0.28
- Paper LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. DOI 10.1186/s12951-025-03550-4 ↗
Zhuo Wu · 1 shared paper, 2025 · strength 0.28
- Paper LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. DOI 10.1186/s12951-025-03550-4 ↗
Zhou Fang · 1 shared paper, 2025 · strength 0.28
- Paper LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. DOI 10.1186/s12951-025-03550-4 ↗
Rufu Chen · 1 shared paper, 2025 · strength 0.28
- Paper LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. DOI 10.1186/s12951-025-03550-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.